Company intelligence / Profile preview

Pfenex Inc.

San Diego, California, United Statesprimrosebio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pfenex was acquired by Ligand Pharmaceuticals in 2020. Prior to acquisition, they had several products in development and some approved products including a biosimilar to Forteo (teriparatide) for osteoporosis treatment. Their platform technology has been used in multiple approved vaccines and therapeutics.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: Proteinsantibody derivativesenzymespeptidescytokinesantigensvaccinesnanobodies
Industry: Biotech

Drug pipeline

2 assets

teriparatide

Commercial

Indications: Osteoporosis

1 more asset in the full pipeline.

Request access →

Partnerships

Serum Institute of IndiaAlvogenMerck & Co.Jazz Pharmaceuticals

Beyond the preview

Go deeper on Pfenex Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pfenex Inc..

Explore the full profile